Breviscapine can treat coronary disease .  Breviscapine inhibits the increased levels of 4-HNE and 8-OHdG, and enhances the antioxidant capacity of cortex tissue.  Breviscapine can reduce the inflammatory response, protect the lungs from inflammatory cascade responses by inhibiting the expression of IL-18 and ICAM-1.  Breviscapine injection significantly ameliorates neurologic deficit, reduces infarct volume and water content, and suppresses the levels of NSE in a time-dependent manner, may the mechanism is by up-regulating the expression of Nrf2/HO-1 pathway .Scutellarin has many pharmacological effects, such as antioxidant, antitumor, antiviral, neuroprotection and antiinflammatory activities. It down-regulates the STAT3/Girdin/Akt signaling in HCC cells, and inhibits RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts.

C₂₁H₁₈O₁₂

DMSO